
Rx Rundown: Novo Nordisk, Pathos AI, GSK and more
Deals: Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 billion, including $200 million upfront. GSK is paying $1.2 billion upfront to Boston Pharmaceuticals for an experimental …